Lipocine to host R&D event July 9, 2025 on LPCN 1154 for postpartum depression; Phase 3 data Q2 2026

Lipocine Inc.

Virtual R&D investor event on July 9, 2025 at 11 AM ET to discuss LPCN 1154 (BRLIZIO) for postpartum depression (PPD).
Phase 3 registrational study recently initiated; top-line data expected in Q2 2026.
Event features Dr. Kristina Deligiannidis; includes clinical, regulatory, and development updates with Q&A.
LPCN 1154 is an oral brexanolone formulation targeting rapid symptom relief with 48-hour outpatient treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.